Skip to main content

Table 1 Demographic, clinical, radiological and follow-up of entire cohort and suspected or confimed COVID-19 cohort

From: Impact of COVID-19 pandemic in natural course of Moyamoya Angiopathy: an experience from tertiary-care-center in India

  Entire cohort (n = 74) Suspected or confirmed COVID-19 cohort (n = 14)
1. Mean age (years) 23.5 ± 16.1 17.6 ± 16.1
2. Pediatric MMA 52.7% 78.6%
3. Adult MMA 47.3% 21.4%
4. Male:Female 1:1.24 1:1
5. Area of residence
 Rural 64.9% 71.4%
 Urban 35.1% 28.6%
6. Duration of disease (months) 41.4 ± 31.5 36.3 ± 12.9
7. “MMA” type
 TIA 2.7% 7.1%
 Frequent TIA 16.2% 35.7%
 Cerebral infarction 62.2% 57.1%
 Intracerebral hemorrhage 8.1% 0%
 Headache 5.4% 0%
 Epilepsy 5.4% 0%
 Asymptomatic 0% 0%
 Others 0% 0%
8. Previously documented radiological lesion in brain
 Infarct 85.1% 78.6%
 Hemorrhage 6.8% 0%
 No acute lesion 8.1% 21.4%
9. Suzuki staging in the last documented in angiography
 Stage I 0% 0%
 Stage II 9.5% 7.1%
 Stage III 29.7% 28.6%
 Stage IV 37.8% 50.0%
 Stage V 21.6% 14.2%
 Stage VI 1.4% 0%
10. Time since last follow-up (months) 9.2 ± 1.7 9.6 ± 1.6
11. Compliance to prescribed medications
 Yes 90.5% 92.9%
 No 9.5% 7.1%
12. Neurological symptoms (worsening or new onset)
 Yes 16.2% 64.3%
 No 83.8% 35.7%
  1. n: Number; MMA: Moyamoya angiopathy; TIA: Transient ischemic attack